Scan to Download ios&Android APP


Oxford Biomedica looks to extended AZN tie-in to turn around share price

11:15, 5 July 2022

Share this article
In this article:
  • UK100
    UK 100
    7527.7 USD
    -16.4 -0.220%

What You Need to Know

The week ahead update on major market events in your inbox every week. Subscribe
Astra Zeneca office in the US. Photo:Shutterstock
Vaccine extension deal with Astra Zeneca could be good news for Oxford Biomedica. Photo:Shutterstock

Oxford Biomedica (OXB) has just signed an agreement to extend by three years its vaccine development joint venture with AstraZeneca.

The market analyst Liberum, in a note yesterday, said that it has put at least one bear argument to bed as it retained its buy recommendation and target price of £13.90 - the Oxford Biomedica share price currently stands at 450p, implying massive upside potential.

In the note Edward Thomason at Liberum said: “This new deal provides a path for generating revenue beyond 2022, although there is no reservation fee as part of the new master service agreement.

Thomason added that the deal gives partial answers to one of the bear concerns for OXB, showing that OXB can deliver on high-quality adeno-viral vector manufacture and secure repeat work.

“OXB’s shares have fallen significantly from last year’s highs despite good strategic progress in shaping the core CDMO (Contract Development and Manufacturing Organisation Outsourcing) business. However, OXB now has significant capacity in place in the UK and US, and needs to deliver new collaborations to capitalise on this opportunity,” he said.

What is your sentiment on OXB?

5.070
Bullish
or
Bearish
Vote to see Traders sentiment!

Oxford Biomedica share price chart

Covid jabs a permanent fixture?

Danni Hewson, financial analyst at AJ Bell recognises the potential upside from this extension but is keen to point out a number of uncertainties too.

“It’s clear that the fortunes of Oxford Biomedica are currently tied to the spread of Covid-19. Will governments decide to implement a fourth vaccine rollout, will variants require constant adjustments and will a covid jab become a permanent part of our winter health prep?”

She adds: “The extension of a partnership with AstraZeneca is potentially fantastic news for the company’s revenue stream. It had warned investors to see 2021 as a blip and said the outlook for future revenues had shrunk which is predominantly behind the 63% drop in its share price since the start of the year.”

“A further rollout would change the calculations and analysts see a huge upside to this company. But there are no guarantees that this jab would form part of a Western covid protocol and the drug is still not cleared for use in the USA. However, the events of the last few years, coupled with warnings not to be complacent does focus minds and present opportunities even if there are no guarantees.”

Read more

What You Need to Know

The week ahead update on major market events in your inbox every week. Subscribe
The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?


Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account

2. Make your first deposit

3. You’re all set. Start trading